Evaluation of new treatments for GBS using real-world data
Date published: May 9, 2024
A substantial proportion of patients with GBS do not respond sufficiently to the current proven effective treatment with intravenous immunoglobulins (IVIg) or plasma exchange. The rarity of the disease challenges the conduct of clinical trials, with no new effective treatments found in the past 30 years. Improved designs for conducting treatment studies and novel treatment options are urgently needed.
In this proof-of-concept study we aim to evaluate the potential to use real-world data to compare the effectiveness of new treatments, by comparing patients treated with a 2nd dose of IVIg within the SID-GBS trial to selected control patients from the International GBS Outcome Study. The results may facilitate the conduct of comparative studies on novel treatments.
A list of research articles
-
The role of B lymphocytes in the progression of chronic immune-mediated neuropathies
-
Study on CIDP
In addition, I am studying the role of B lymphocytes in the progression of chronic immune-mediated neuropathies, including Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Autoimmune Nodopathy (AN). Through this research, we strive to enhance diagnostics, clinical care, and treatment options for patients affected by these conditions.
-
-
Detecting anti-paranodal antibodies
-
Study on GBS
My research primarily focuses on investigating novel pathogenic antibodies in paranodal regions associated with immune-mediated neuropathies. The aim of my project is to improve diagnostic methods for detecting anti-paranodal antibodies and to determine the prevalence of these harmful autoantibodies in patients with Guillain-Barré Syndrome (GBS).
-
-
Time to treatment study
-
Study on GBS
In this project, we aim to describe the current practice of time to treatment. We also assess the association with functional outcome in patients with GBS who received first-line treatment with intravenous immunoglobulin or plasma exchange. This study is performed using data from the International GBS Outcome Study (IGOS).
-
